The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Open accessAbstract
Growth factors mediate their diverse biologic responses (regulation of cellular proliferation, differentiation, migration and survival) by binding to and activating cell-surface receptors with intrinsic protein kinase activity named receptor tyrosine kinases (RTKs). About 60 RTKs have been identified and can be classified into more than 16 different receptor families. Their activity is normally tightly controlled and regulated. Overexpression of RTK proteins or functional alterations caused by mutations in the corresponding genes or abnormal stimulation by autocrine growth factor loops contribute to constitutive RTK signaling, resulting in alterations in the physiological activities of cells. The ErbB receptor family of RTKs comprises four distinct receptors: the EGFR (also known as ErbB1/HER1), ErbB2 (neu, HER2), ErbB3 (HER3) and ErbB4 (HER4). ErbB family members are often overexpressed, amplified, or mutated in many forms of cancer, making them important therapeutic targets. EGFR has been found to be amplified in gliomas and non-small-cell lung carcinoma while ErbB2 amplifications are seen in breast, ovarian, bladder, non-small-cell lung carcinoma, as well as several other tumor types. Several data have shown that ErbB receptor family and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion by modulating extracellular matrix (ECM) components. Recent findings indicate that ECM components such as matrikines bind specifically to EGF receptor and promote cell invasion. In this review, we will present an in-depth overview of the structure, mechanisms, cell signaling, and functions of ErbB family receptors in cell adhesion and migration. Furthermore, we will describe in a last part the new strategies developed in anti-cancer therapy to inhibit ErbB family receptor activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Tumour-cell invasion and migration: diversity and escape mechanisms
Friedl, P., & Wolf, K. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1075 · Cited by 3,222
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Signaling Through Scaffold, Anchoring, and Adaptor Proteins
Pawson, T., & Scott, J. D. (1997) · Science · doi:10.1126/science.278.5346.2075 · Cited by 2,256
Cell adhesion: integrating cytoskeletal dynamics and cellular tension
Parsons, J. T., Horwitz, A. R., & Schwartz, M. A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2957 · Cited by 1,988
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
Morel, A.-P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., & Puisieux, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002888 · Cited by 1,645
Epidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Compensation mechanism in tumor cell migration
Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., Strongin, A. Y., Bröcker, E.-B., & Friedl, P. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209006 · Cited by 1,391
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Protein Tyrosine Kinase Structure and Function
Hubbard, S. R., & Till, J. H. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.373 · Cited by 1,171
Sahai, E., & Marshall, C. J. (2003) · Nature Cell Biology · doi:10.1038/ncb1019 · Cited by 1,147
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 766
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
MEMBRANE-ANCHORED GROWTH FACTORS
Massagué, J., & Pandiella, A. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002503 · Cited by 660
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
Korkaya, H., Paulson, A., Iovino, F., & Wicha, M. S. (2008) · Oncogene · doi:10.1038/onc.2008.207 · Cited by 556
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Cho, H.-S., & Leahy, D. J. (2002) · Science · doi:10.1126/science.1074611 · Cited by 447
The organ microenvironment and cancer metastasis
Fidler, I. J. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700904.x · Cited by 426
Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments
Spring, J., Beck, K., & Chiquet-Ehrismann, R. (1989) · Cell · doi:10.1016/0092-8674(89)90294-8 · Cited by 413
Autocrine, paracrine and juxtacrine signaling by EGFR ligands
Singh, A. B., & Harris, R. C. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.026 · Cited by 400
Tenascin-C induced signaling in cancer
Orend, G., & Chiquet-Ehrismann, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.02.017 · Cited by 384 · cited 1×
“…hexameric glycoprotein of which each subunit contains: the N-terminal assembly domain, a domain composed of 14.5 EGF-like repeats (EGFL), a domain composed of a varied number of fibronectin type III-like repeats, and a fibrinogen-like sequence on the C terminus (Orend and Chiquet-Ehrismann, 2006).”
BackgroundInfluentialThe role of the EGFR signaling in tumor microenvironment
De Luca, A., Carotenuto, A., Rachiglio, A., Gallo, M., Maiello, M. R., Aldinucci, D., Pinto, A., & Normanno, N. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21260 · Cited by 359
Fehm, T., Müller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E., Rack, B., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1163-x · Cited by 353
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 346
Schenk, S., Hintermann, E., Bilban, M., Koshikawa, N., Hojilla, C., Khokha, R., & Quaranta, V. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208145 · Cited by 309
Dawson, J. P., Berger, M. B., Lin, C.-C., Schlessinger, J., Lemmon, M. A., & Ferguson, K. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7734-7742.2005 · Cited by 297
Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor
Swindle, C. S., Tran, K. T., Johnson, T. D., Banerjee, P., Mayes, A. M., Griffith, L., & Wells, A. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200103103 · Cited by 286
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Nygren, P. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06438.x · Cited by 282
Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans, S., & Magez, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307341200 · Cited by 276
Tethered Epidermal Growth Factor Provides a Survival Advantage to Mesenchymal Stem Cells
Fan, V. H., Au, A., Tamama, K., Littrell, R., Richardson, L. B., Wright, J. W., Wells, A., & Griffith, L. G. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0320 · Cited by 269
Zuo, J., Zhu, W., Li, M., Li, X., Yi, H., Zeng, G., Wan, X., He, Q., Li, J., Qu, J., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23175 · Cited by 258
Sunada, H., Magun, B. E., Mendelsohn, J., & MacLeod, C. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3825 · Cited by 253
Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains
Schmitz, K. R., Bagchi, A., Roovers, R. C., van Bergen en Henegouwen, P. M. P., & Ferguson, K. M. (2013) · Structure · doi:10.1016/j.str.2013.05.008 · Cited by 250
Jähnichen, S., Blanchetot, C., Maussang, D., Gonzalez-Pajuelo, M., Chow, K. Y., Bosch, L., De Vrieze, S., Serruys, B., Ulrichts, H., Vandevelde, W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012865107 · Cited by 250
Epidermal growth factor receptor biology (IMC-C225)
Kim, E. S., Khuri, F. R., & Herbst, R. S. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00014 · Cited by 242
Mallini, P., Lennard, T., Kirby, J., & Meeson, A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.008 · Cited by 240
Structural analysis of receptor tyrosine kinases
Hubbard, S. R. (1999) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(98)00047-9 · Cited by 239
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
Bonnomet, A., Syne, L., Brysse, A., Feyereisen, E., Thompson, E. W., Noël, A., Foidart, J.-M., Birembaut, P., Polette, M., & Gilles, C. (2012) · Oncogene · doi:10.1038/onc.2011.540 · Cited by 201
Tyrosine kinase receptors as attractive targets of cancer therapy
Bennasroune, A., Gardin, A., Aunis, D., Crémel, G., & Hubert, P. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.08.004 · Cited by 197
Self-citationThe extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand
Bouyain, S., Longo, P. A., Li, S., Ferguson, K. M., & Leahy, D. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507591102 · Cited by 192
Epidermal growth factor receptor
Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T. P. J., Ward, C. W., & Burgess, A. W. (2003) · The EGF Receptor Family · doi:10.1016/b978-012160281-9/50004-9 · Cited by 181
Cell Motility and Cytoskeletal Regulation in Invasion and Metastasis
Kedrin, D., van Rheenen, J., Hernandez, L., Condeelis, J., & Segall, J. E. (2007) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-007-9046-4 · Cited by 178
Fuller, S. J., Sivarajah, K., & Sugden, P. H. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.02.278 · Cited by 175
Prieto, A. L., Andersson-Fisone, C., & Crossin, K. L. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.663 · Cited by 172
Kallergi, G., Agelaki, S., Kalykaki, A., Stournaras, C., Mavroudis, D., & Georgoulias, V. (2008) · Breast Cancer Research · doi:10.1186/bcr2149 · Cited by 155
Lorch, J. H., Klessner, J. L., Park, J., Getsios, S., Wu, Y., Stack, M. S., & Green, K. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405123200 · Cited by 147
Friedman, M., Nordberg, E., Höidén‐Guthenberg, I., Brismar, H., Adams, G. P., Nilsson, F. Y., Carlsson, J., & Ståhl, S. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm011 · Cited by 146
Yue, P., Zhang, X., Paladino, D., Sengupta, B., Ahmad, S., Holloway, R. W., Ingersoll, S. B., & Turkson, J. (2011) · Oncogene · doi:10.1038/onc.2011.409 · Cited by 140
EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas
Moustafa, A. A., Achkhar, A., & Yasmeen, A. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s292 · Cited by 128
Transmembrane Peptides as Inhibitors of ErbB Receptor Signaling
Bennasroune, A., Fickova, M., Gardin, A., Dirrig‐Grosch, S., Aunis, D., Crémel, G., & Hubert, P. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-10-0753 · Cited by 115
Self-citationTargeting the HER/EGFR/ErbB Family to Prevent Breast Cancer
Howe, L. R., & Brown, P. H. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0334 · Cited by 102
Riese, D. J., Gallo, R. M., & Settleman, J. E. (2007) · BioEssays · doi:10.1002/bies.20582 · Cited by 93
Cell and Molecular Biology of Epidermal Growth Factor Receptor
Ceresa, B. P., & Peterson, J. L. (2014) · International review of cytology · doi:10.1016/b978-0-12-800177-6.00005-0 · Cited by 85
Emerging concepts in the regulation of the EGF receptor and other receptor tyrosine kinases
Endres, N., Barros, T. F., Cantor, A. J., & Kuriyan, J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.001 · Cited by 82
Iyer, A. K. V., Tran, K. T., Griffith, L. G., & Wells, A. H. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21232 · Cited by 78
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh, V. (2015) · BioDrugs · doi:10.1007/s40259-015-0130-9 · Cited by 73
Stemming Resistance to HER-2 Targeted Therapy
Bedard, P. L., Cardoso, F., & Piccart, M. J. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9116-x · Cited by 71
Iyer, A. K. V., Tran, K. T., Borysenko, C. W., Cascio, M., Camacho, C. J., Blair, H. C., Bahar, İ., & Wells, A. H. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20986 · Cited by 69
Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule
Friedman, M., Lindström, S., Ekerljung, L., Svahn, H. A., Carlsson, J., Brismar, H., Gedda, L., Frejd, F. Y., & Ståhl, S. (2009) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090096 · Cited by 67
Bhat‐Nakshatri, P., Goswami, C. P., Badve, S., Sledge, G. W., & Nakshatri, H. (2013) · Scientific Reports · doi:10.1038/srep02530 · Cited by 65
Zhan, L., Xiang, B., & Muthuswamy, S. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4081 · Cited by 60
Feigin, M. E., & Muthuswamy, S. K. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.034 · Cited by 55
Arpel, A., Sawma, P., Spenlé, C., Fritz, J., Meyer, L. A. T., Garnier, N., Velázquez-Quesada, I., Hussenet, T., Aci‐Sèche, S., Baumlin, N., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.044 · Cited by 52
Self-citationRodrigues, M., Blair, H. C., Stockdale, L., Griffith, L. G., & Wells, A. H. (2012) · Stem Cells · doi:10.1002/stem.1215 · Cited by 52
HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
Zieliński, R., Lyakhov, I. G., Hassan, M., Kuban, M., Shafer-Weaver, K., Gandjbakhche, A., & Capala, J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2887 · Cited by 51
Giltnane, J. M., Moeder, C. B., Camp, R. L., & Rimm, D. L. (2009) · Cancer · doi:10.1002/cncr.24277 · Cited by 50
Liu, A., Garg, P., Yang, S., Gong, P., Pallero, M. A., Annis, D. S., Liu, Y., Passaniti, A., Mann, D. L., Mosher, D. F., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809198200 · Cited by 50
Kuo, P., Huang, M., Cheng, D.-E., Hung, J., Yang, C., & Chou, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.321190 · Cited by 47
Jeon, M., Lee, J., Nam, S. J., Shin, I., Lee, J. E., & Kim, S. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.02.019 · Cited by 43
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics
Alaoui‐Jamali, M. A., Morand, G. B., & da Silva, S. D. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00017 · Cited by 36
Fichter, C. D., Gudernatsch, V., Przypadlo, C. M., Follo, M., Schmidt, G., Werner, M., & Laßmann, S. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1187-5 · Cited by 36
Emerging protein kinase inhibitors for non-small cell lung cancer
Liu, S. V., Subramaniam, D. S., Cyriac, G., Khalek, F. J. A., & Giaccone, G. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.873403 · Cited by 28
Cited by
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Guidelines for the use of flow cytometry and cell sorting in immunological studies *
Cossarizza, A., Chang, H., Radbruch, A., Akdis, M., Andrä, I., Annunziato, F., Bacher, P., Barnaba, V., Battistini, L., Bauer, W. M., et al. (2017) · European Journal of Immunology · doi:10.1002/eji.201646632 · Cited by 542
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Liu, X., Si, W., He, L., Yang, J., Peng, Y., Ren, J., Liu, X., Jin, T., Yu, H., Zhang, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00774-2 · Cited by 97
Metadata
- Authors
- Appert-Collin, A., Hubert, P., Crémel, G., & Bennasroune, A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2015-11-24
- Volume
- 6
- Pages
- 283-283
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2204638621
- Cited by
- 310
- References
- 85
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.